Personalized Ovarian Cancer Treatment
Options Are One Call Away Call Now
Envita Medical Centers building

Early, Late-Stage, and Metastatic Ovarian Cancer Treatment Options

Advanced New Ovarian Cancer Treatments Designed to Potentially Achieve Long-Term Remission

If the core causes of your ovarian cancer remain untreated, then a complete remission from the disease may not last for long. We aim to overcome the potential limitations of standard ovarian cancer treatment at Envita Medical Centers, a world-class integrative center for precision oncology, by utilizing advanced new treatments which go beyond the scope of conventional chemotherapy, radiation therapy, immunotherapy, hysterectomy, and other options.

Our integrative physicians have been treating all types and stages of ovarian cancers for over 20 years, with advanced personalized immunotherapies and a combination of several proprietary new treatments, such as CIPI™ (Chemo Immuno Precision Injections) and GTFC™ (Genetically Targeted Fractionated Chemotherapy). These treatments are custom designed to strike at the root causes of cancer, even advanced ovarian cancers, and may help in sustaining long-term remissions when combined into a precision protocol built for our patients’ specific needs.

Our clinical experience of over 20 years in treating both chronic infections and late-stage cancers, enable us to go beyond standard treatments like radiation therapy, brachytherapy, chemoradiation, cone biopsy or conization, and surgeries including radical hysterectomy, radical trachelectomy, and pelvic exenteration.

Hear From JoAnn, who Sought a Precision-Targeted Protocol After Experiencing Multiple Recurrences

Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.

This article covers basic facts about ovarian cancer including:

How Envita Aims to Overcome the Challenges of Standard Ovarian Cancer Treatment

In our clinical opinion, the one-size-fits all treatment regimens based on ovarian cancer type and stage may not be enough to combat the disease. Most patients, like JoAnn experience a high-risk of recurrence despite going through maintenance therapy after the initial response to their first-line treatment based on the NCCN (National Comprehensive Cancer Network) guidelines. Maintenance therapy, as defined by the National Cancer Institute, is given to help keep cancer from coming back after it has disappeared following the initial therapy.

According to the American Cancer Society’s report based on patient outcomes across standard cancer centers, which typically follow the NCCN guidelines, the 5-year relative survival rate of ovarian cancer is 49%, highlighting the lack of response to conventional care in most ovarian cancer patients.

Cancer is a disease of genetic mutations, genomics, messaging, and immunity, not simply tissue or tumor types and staging patterns, which explains why a tumor type and stage-based treatment is not always enough to overcome the disease.

If the unique set of causes responsible for each patient’s cancer is not targeted in their treatment early on, then the ovarian cancer cells mutate faster, rendering treatment ineffective. To counter these challenges and combat the disease, we breakaway from the cookie-cutter treatment approach and provide the benefits of personalized precision oncology, which is a game changer in ovarian cancer treatment.
Dr. Dino Prato NMD
Founder/CEO Envita Medical Centers

Detailed Case Study Outlining the Efficacy of Advanced Precision Oncology in Treating a Stage 4 Recurrent Metastatic Ovarian Carcinoma Patient

Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.

Personalized precision oncology treatments are crucial for attacking the core causes of the ovarian cancer, but precision is largely missing in standard oncology treatment planning, as the NCCN guidelines do not allow healthcare providers to deviate much from the tumor type and stage-based treatment protocols.

Envita Medical Centers
Medical Team

Physicians with MD, NMD, DO, DO(h), MD(h), medical licenses
22
Pharmacists specializing in integrative agents
7
Nurses trained in precision treatment delivery
40+

You may be wondering how is it possible for Envita to go beyond the NCCN guidelines?

The NCCN guidelines derive “effective” cancer treatment options based off large generic clinical trials determined by cancer type and staging, without taking into account the patient’s genetic mutations. Envita, being a truly integrative clinic, is not bound by the NCCN restrictions, which enables us to treat you, the patient, as an individual whose unique mutations have caused the genetic disease. Our personalized treatment options are designed to precision-target each of those distinct mutations, giving patients even in advanced stages, such as stage III and stage IV, a better chance at long-term remissions. Envita’s patient-specific treatments include a powerful combination of the latest in conventional and natural medicines, which effectively work towards building the patient’s immune system while attacking the cancerous cells in the body.

In the precision medicine era, detecting and genetically characterizing residual disease after standard treatment will be invaluable for improving patient outcomes [1]. According to this medical study, “without methods to accurately and rapidly detect residual disease, an early critical window to modify treatment is therefore lost,” which is why at Envita we focus on monitoring and treating the disease in real-time.

Your unique ovarian cancer is constantly mutating and changing to fight against treatment options thrown at it, reiterating the need for precision oncology options to aim at where your cancer is going rather than where it has been. Proactively treating the disease is key to reducing the risk of chemoresistance, one of the crucial challenges in ovarian cancer treatment.

What is Chemoresistance?

Chemoresistance refers to the ability of cancer cells to evade the effect of anti-cancer medicines by pumping them out of the cells. Recent studies suggest that intra-tumor heterogeneity (ITH) is the main cause of treatment failure by chemoresistance in many types of cancers including ovarian cancer [2]. ITH increases the ability of tumors to adapt to an incompatible microenvironment, which is why the development of novel strategies to overcome chemoresistance is the central goal in ovarian cancer research.

Pgp pumping chemotherapy drugs out of a cancer cell
Learn Learn more about Chemotherapeutic Drug Resistance

Personalized Precision Oncology Takes Cancer Care to the Next Level

The interaction of cancer cells with microenvironment modulates tumor heterogeneity, affecting the response to therapy. Precision care helps in better understanding the complex cancer microenvironment, but patients do not get access to precision till they fail NCCN guided first-line treatments, based on tumor type and stage.

At Envita, Precision Oncology Forms the Core of Your Unique Personalized Treatment!

Envita Medical Centers building

The handful of patients who gain access to precision care, receive a watered-down version of Envita’s detailed precision algorithms, which are crucial to understand patient-specific cancer drivers, their tumor microenvironment, and all other factors that can impact their disease progression and treatment outcomes. To provide a comprehensive approach for combating your disease, our detailed precision algorithms map your genetics, epigenetics, and miRNA (microRNA) in addition to testing for heavy metals, toxins, and infections, which aid in treating the root cause of your ovarian cancer.

Envita’s Detailed Precision Algorithms Treat Your Cancer at Multiple Levels!

Envita Precision Algorithm vs.
Standard Oncology Precision Testing

RNA Transcriptome Genes
Envita Medical Centers: 20,000+
Standard Oncology: Unchecked
SNV/CNV Genes
Envita Medical Centers: 452
Standard Oncology: 309
Rearrangements/Fusion Genes
Envita Medical Centers: 51
Standard Oncology: 27
Microsatellite Instability (MSI)
Envita Medical Centers: Checked
Standard Oncology: Checked
Tumor Mutation Burden (TMB)
Envita Medical Centers: Checked
Standard Oncology: Checked
BRCA 1/2
Envita Medical Centers: Checked
Standard Oncology: Checked
Immunohistochemistry
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Chemosensitivity
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Concurrent Liquid Biopsy
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Exosomal miRNA Analysis
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Circulating Tumor Cells Enumeration
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Pharmacogenomics
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Individualized Therapy Recommendation
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Carcinogenic Exposure - Root Causes
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Inflammation Markers
Envita Medical Centers: Checked
Standard Oncology: Unchecked
Metabolic Target Drivers
Envita Medical Centers: Checked
Standard Oncology: Unchecked

*Individual results may vary. Envita makes no guarantees for outcomes.

Our precision algorithm helps us to personalize treatments designed for attacking the core causative factors of your unique cancer, while reducing chances of metastatic spread to various parts of the body, such as the lymph nodes, peritoneum, omentum, liver, lungs, or brain. A study published in the “American Journal of Obstetrics and Gynecology,” shows how even in the early stages of the disease, due to an aggressive spread pattern, a substantial part of patients have occult metastasis [3]. Envita’s detailed precision algorithms are designed to identify such early signs of metastasis and help patients progress towards a long-term remission.

Learn more about Metastasis

Targeted New Treatments to Potentially Improve Outcomes in All Stages of Ovarian Cancer

At Envita, targeted therapies are not just one of the treatment options for ovarian cancer, rather all our treatments are targeted to attack each patient’s unique set of causes responsible for the growth and spread of their disease. This level of personalization aims to uproot the disease and rebuild your immune system’s ability to check potential chances of recurrence, which explains why it is crucial for both early as well as late stages of ovarian cancer.

Our unique treatments are designed on the N-of-1 model, which is like a single-subject clinical trial. The entire treatment plan is focused on targeting each patient’s unique ovarian cancer expressions, closely monitoring their disease, and modifying treatment, when needed, to proactively curb potential recurrence and metastases. A reactivated immune system is crucial in sustaining long term remission, leading to a holistic recovery from ovarian cancer.

Envita’s personalized precision oncology is a four-step process with the goal of improving quality of life, increasing longevity, and reducing toxicity in this area of gynecologic oncology.

Graph depicting Envita Medical Centers' method

Step 1

Genomic Identification Decodes the Root Cause of Your Ovarian Cancer

Treating the root cause of your cancer is a key component of our multi-faceted treatment approach. Inherited genetic irregularities, such as mutations in the BRCA 1 and BRCA 2 genes, are commonly linked to an increased risk of ovarian and breast cancer [4], which explains why family history can be a risk-factor in certain cancers. About 44% of women with a BRCA 1 gene mutation and 17% of those with a BRCA 2 gene mutation are expected to develop ovarian cancer in their lifetime.

Graph depicting Envita Medical Centers' method
Adapted from: Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284-296. doi:10.3322/caac.21456

The BRCA genes are responsible for suppressing tumor growth, but mutated BRCA genes are incapable of functioning properly, thus increasing the risk of cancer. The BRCA genes are critical when focusing on ovarian cancer treatment, but at Envita, we understand that many more genes can be identified as potential treatment targets, which led us to develop state-of-the-art genomic identification techniques.

Our in-depth and world-class genetic testing goes far beyond what most other cancer centers can offer in the realm of genomics. We work with the most advanced laboratories from around the world to develop detailed testing, which lays the foundation to our unique precision-targeted integrative treatments.

Envita’s detailed testing not only decodes each patient’s genetic and epigenetic targets, but it also identifies other potential causes which could be environmental or related to infectious diseases. Envita’s peer-reviewed and published paper on "Cancer and Infectious Causes" elucidates this complex connection, which helps to dive into the root of each patient’s specific cause of cancer [5]. Our proprietary testing and expertise in treating infections, helps determine the possible infectious or environmental causes affecting your cancer and your response to treatment.

Once all the potential causes linked to your unique ovarian cancer are determined, we utilize personalized treatment methods to attack patient-specific ovarian cancer expressions. Our enhanced detoxification technology removes toxins, chemicals, and infectious die-off from your blood supply, paving the way for an optimized treatment response.

Learn more about Genomic Analysis

Step 2

Immune System Targeting Helps Reduce the Risk of Chemoresistance

The immune system is an important weapon against cancer and by treating your immune system through proprietary immunotherapies, detoxification, and nutrition, we can help your body combat your condition. The information we gather through our extensive genomic analysis allows us to develop immunotherapy options, designed with the goal of rebuilding and training your immune system to target your cancer. A healthy and reactivated immune system is better equipped to tackle chemoresistance, offering you the best chances of a holistic recovery.

Most cancer centers that do genetic testing, base their results on an old tissue biopsy, which may not be an accurate representation of the current genetic targets as the cancer mutates fast. To affect the current genetic targets and proactively treat the disease, we analyze the most recent mutations through Envita’s Ultra Analytes Liquid Biopsy.

Ultra Analytes Liquid Biopsy
Ultra Analytes Liquid Biopsy is deployed to identify targeted immunotherapy options to help get your immune system working properly again. Learn more about Immunotherapy

Our liquid biopsy is a blood test to gather crucial information about the genetics of your circulating ovarian cancer cells, which helps us in custom-building a multitargeted and multifaceted treatment protocol. This information forms the backbone of our unique personalized precision oncology treatments and makes our approach more advanced than other cancer centers.

At Envita, we go beyond basic targeted immunotherapies, such as PARP inhibitors and smart drugs, that have been helpful in treating ovarian cancer but may not always be enough. Our advanced research in immunotherapy for over two decades shows how genomically reprogramming your immune system cells, like natural killer (NK) cells and dendritic cells, to identify cancer cells and mark them for immune response may help in optimizing treatment results [6]. We offer several innovative precision-targeted immunotherapies to actively address the immune system, as well as directly treat your unique ovarian cancer expressions.

Step 3

Personalized Drug Design Builds a Comprehensive Treatment Plan

We use a combination of FDA (Food and Drug Administration) approved drugs, repurposed drugs, and custom-compounded adjuvants to affect patient-specific ovarian cancer biomarkers. Biomarkers are attributes of cancer cells containing specific chemotherapy and immunotherapy targets. Not all biomarkers, determined via our in-depth testing, can be impacted by the anti-cancer medicines currently available on the market. To bridge this gap and build a truly comprehensive treatment plan, we custom-compound adjuvants at our in-house pharmacy

FDA Approved Drugs
Optimized for your cancer mutations.
Repurposed Drugs
Off-label use of approved medications
Custom Compounded Adjuvants
Genetically typed for each patient.

Our custom-compounded adjuvants are based on advanced phytotherapeutics, including plant extracts and herbs. You may not be aware that many of the current oncology drugs are derived from phytotherapeutics, which makes plant-based drugs excellent adjuvants for cancer treatment. These adjuvants may address the anomalies at cellular and molecular levels to help you proceed towards recovery. For instance, the patient-specific epigenetic information gathered via our detailed testing is used to design medications which potentially promotes the expression of tumor suppressant genes, like BRCA 1 and 2, and block oncogenes that facilitate tumor growth.

As part of our personalized precision- targeted treatments, we also adjust the dosage of FDA approved and repurposed drugs to reduce their toxicity and optimize benefits. Not every patient metabolizes at the same rate, which is why adjusting drug dosage is crucial to ensure that the medicines have the desired effect.

Learn more about Personalized Drug Design

Step 4

Precision Deployment of New Treatments for a Holistic Recovery

Our innovative precision deployment mechanisms go beyond standard bilateral salpingo-oophorectomy (removal of both ovaries and fallopian tubes) and cytoreductive surgeries, to reduce side effects of treatment in this area of gynecologic oncology. Envita’s proprietary technologies are designed to cause minimum impact to the healthy cells surrounding the cancerous cells, unlike the negative effects experienced through maximum therapeutic dose chemotherapy.

In our clinical opinion, maximum dose untargeted chemotherapy can harm more than it helps when the wrong chemotherapy agents are selected, and most ovarian cancer patients need chemotherapy, either before or after a tumor debulking surgery. These mismatched chemotherapy agents can weaken the patient’s overall immune system, allowing the cancer to become even more resistant leading to further spread.

To overcome this challenge, Envita Medical Centers’ personalized precision deployment mechanisms include advanced immuno agents while offering the benefits of the latest treatments, such as intraperitoneal chemotherapies, used in ovarian and other peritoneal cancers. Peritoneum is one of the most common sites of metastasis in cases of ovarian carcinomas.

We use intravenous deployment and interventional radiology procedures to offer a personalized and precision-targeted treatment which provides the best possible chance of responding to care.  Some of our advanced proprietary treatments are as follows:

GTFC™ (Genetically Targeted Fractionated Chemotherapy)

GTFC™ (Genetically Targeted Fractionated Chemotherapy) was developed with the goal of being more efficient at treating real-time genetic targets of the cancer, while reducing major side-effects by sparing the immune system and even reactivating it. This specialized targeted treatment is unique because it increases the bioavailability of the anti-cancer medications, as they are better absorbed by the cancerous cells.

The GTFC™ protocol is designed to best attack and kill your unique form of ovarian cancer by considering your distinct chemo susceptibility and the molecular profiles of your specific ovarian cancer. It takes the guesswork out of your ovarian cancer treatment by utilizing the chemo drugs with the highest potential of impacting each patient’s unique biomarkers. The knowledge of the appropriate chemo medicines for each individual patient allows us to use small doses of multiple chemo agents, increasing the mechanism of action against your specific cancer.

Envita's GTFC™ vs.
Standard Chemotherapy

Helps to improve chemotherapy delivery to the tumor using a "Trojan Horse" delivery mechanism.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Uses genetic molecular profiling to understand all the facets of each patient's specific cancer.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Uses targeted treatment to enhance the mechanism of cancer kill.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Uses microdosed (fractionated) chemotherapies, reducing the chances of impacting healthy cells.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Minimizes toxicity to normal cells, lowering the chance of side-effects related to administration.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Uses patient-specific supportive immunotherapy to strengthen the immune system.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Aims to reduce multidrug resistance by administering 10 - 20% of the medication delivered in maximum dose chemo.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked
Allows custom-compounded medications to be readministered in tandem to suit each patient's individual cancer mutations.
Envita's GTFC™: Checked
Standard Chemotherapy: Unchecked

*Individual results may vary. Envita makes no guarantees for outcomes.

Learn more about Genetically Targeted Fractionated Chemotherapy

CIPI™ (Chemo Immuno Precision Injections)

CIPI™ (Chemo Immuno Precision Injections) is a game-changer for ovarian cancer patients who may have been unresponsive to conventional standard of care chemotherapy procedures. It is Envita’s proprietary ovarian cancer treatment option, which takes advantage of the targeted low-dose chemotherapy paradigm. This unique form of chemoembolization directly targets the tumor site with precision delivery of custom-tailored chemotherapy cocktails combined with personalized immunotherapy adjuvant care. Patient-specific micro-dosed chemotherapy and genetically targeted adjunctive immunotherapy attack the tumor site, while potentially minimizing the detrimental side effects to the surrounding healthy cells and tissues.

Envita's CIPI™ vs.
Standard Surgery

Minimally invasive so it can be performed within 40-50 minutes, without the need for large surgical incisions.
Envita's CIPI™: Checked
Standard Surgery: Unchecked
Can be performed multiple times, even at close intervals, because there is minimal risk of post-op complications.
Envita's CIPI™: Checked
Standard Surgery: Unchecked
No need for general anesthesia, reducing the health risks that can result from being put into a medically induced coma to perform an invasive surgery.
Envita's CIPI™: Checked
Standard Surgery: Unchecked
Faster recovery time as compared to traditional surgery, due to the minimally invasive administration.
Envita's CIPI™: Checked
Standard Surgery: Unchecked
Provides direct tumor targeting, which delivers patient-specific genomic agents into the tumor.
Envita's CIPI™: Checked
Standard Surgery: Unchecked
Causes a systemic immune response where the immune system is reactivated to find and attack other metastatic cancer sites in the body.
Envita's CIPI™: Checked
Standard Surgery: Unchecked
Performed by highly trained medical professionals in an outpatient setting, so there is no need of hospital stays for recovery.
Envita's CIPI™: Checked
Standard Surgery: Unchecked

*Individual results may vary. Envita makes no guarantees for outcomes.

Learn more about CIPI™

Types of Ovarian Cancer

Ovarian Cancer is divided and subdivided as follows:

  • Epithelial ovarian cancer: Is the most common form of ovarian carcinoma, generally affecting women older than 65. This form of ovarian cancer starts in the surface layer covering the ovary. Depending on the cancer cell type, epithelial ovarian cancer is further sub-divided into High-Grade Serous Carcinomas (HGSC), Low-Grade Serous Carcinomas (LGSC), Endometrioid, and Mucinous.
  • Ovarian stromal tumors: Originates in the structural tissue cells that hold the ovary together and are responsible for producing the female hormones estrogen and progesterone.
  • Germ cell tumors of the ovary: Begins in the reproductive cells of the ovaries and is a rare type of ovarian cancer.
  • Fallopian tube cancer: Originates in the fallopian tubes connecting the uterus to the ovaries and is an exceedingly rare form of gynecologic cancer.

Symptoms of Ovarian Cancer

Some of the symptoms to watch out for:

  • Abdominal pain
  • Bloating
  • Extreme fatigue
  • Back pain
  • Upset stomach
  • Unexplained weight loss
  • Changes in menstrual cycle, such as heavier or irregular bleeding

Call us Today

Call Now

With all the research and development Envita does to customize and tailor our treatment options, it becomes clear that Envita is in a league of its own. Based on our own patients' statements over the years and our clinical opinion, Envita operates at a higher personalized integrative level, and we offer one-of-a-kind personalized integrative treatment options with unmatched care and compassion. Our expert team undergoes extensive training of over 1,500 hours to adapt to our unique approach of personalized precision oncology designed to potentiate treatment benefits. If you or your loved ones have questions about ovarian cancer, please contact our Patient Care Coordinator team at: 866-830-4576. May God bless you on your journey to healing.

References

[1] Schwartz M, Camacho-Vanegas O, Wood AM, et al. Applying Precision Medicine to Ovarian Cancer: Proof-of-Principle for a "Molecular Second Look". Int J Gynecol Cancer. 2018;28(3):479-485. doi:10.1097/IGC.0000000000001190

[2] Kim S, Han Y, Kim SI, Kim HS, Kim SJ, Song YS. Tumor evolution and chemoresistance in ovarian cancer. NPJ Precis Oncol. 2018;2:20. Published 2018 Sep 17. doi:10.1038/s41698-018-0063-0

[3] Ayhan A, Gultekin M, Celik NY, et al. Occult metastasis in early ovarian cancers: risk factors and associated prognosis. Am J Obstet Gynecol. 2007;196(1):81.e1-81.e816. doi:10.1016/j.ajog.2006.08.043

[4] Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416. doi:10.1001/jama.2017.7112

[5] Smith, A. , Oertle, J. and Prato, D. (2014) Cancer and Infectious Causes. Open Journal of Medical Microbiology, 4, 161-177. doi: 10.4236/ojmm.2014.43019.

[6] Smith, A. , Oertle, J. and Prato, D. (2014) Immunotherapy in Cancer Treatment. Open Journal of Medical Microbiology, 4, 178-191. doi: 10.4236/ojmm.2014.43020.

Choose Envita Medical Centers

Our team is ready to help you get your life back! Please enter your contact information and a Patient Care Expert will contact you shortly. If you would rather speak now, please give us a call at 1-866-830-4576 .

Please fill out your first name.
Please fill out your last name.
Please fill out your phone number.
Please fill out your email address.
Please make a selection.
Please make a selection.
You may request a call back from 8am-5pm Pacific Time. We cannot guarantee that you will receive a callback during your requested time, but we will do our best to contact you as soon as possible.
Please make a selection.
Please make a selection.
Please make a selection.
Max. 1000 characters. Do not include any web urls.
Please fill out your inquiry.